Monroe-based Blue Earth Diagnostics Ltd., a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography radiopharmaceuticals, on Tuesday announced the appointment of Marco Campione as its new CEO, reporting to Bracco Imaging CEO Fulvio Renoldi Bracco.
Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as executive director and global head of contrast media, general manager of pharmaceutical diagnostics North America, and president of GE HealthCare Inc.
Campione also joins the Blue Earth Diagnostics Ltd. board of directors and will serve as vice chair of the Blue Earth Diagnostics Inc. board of directors. David Gauden, a co-founder of Blue Earth Diagnostics and with the company since 2014, assumes the role of full-time CEO of Bracco subsidiary Blue Earth Therapeutics. The changes reflect a carefully planned strategy to drive continued growth, development and opportunity for both companies and Bracco.
“I congratulate Marco Campione on this CEO appointment, and we look forward to drawing upon his strategic, operational and broad general business expertise as we increase our global leadership throughout the diagnostic radiopharmaceutical industry,” Fulvio Renoldi Bracco said. “Marco joins the Bracco Group at a transformative point in our evolution, as the company matures, broadens its horizons globally and expands its commercial presence.
“I also want to take this opportunity to recognize the many contributions of David Gauden in advancing the success of Blue Earth Diagnostics, and I wish him the best of success in now leading Blue Earth Therapeutics as its full-time CEO.”
“I am excited and honored to assume the role of CEO at Blue Earth Diagnostics,” Campione said. “The company is a recognized leader throughout the nuclear medicine and oncology communities, having a strong reputation grounded in successful innovation, execution and dedicated service on behalf of patient health. I look forward to applying my experience towards expanding availability of the Company’s PET imaging products for prostate cancer, advancing its development programs in PET neuro-oncology and solid tumors, and in exploring additional opportunities and collaborations.”
